Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age.


Bejon, P; Lusingu, J; Olotu, A; Leach, A; Lievens, M; Vekemans, J; Mshamu, S; Lang, T; Gould, J; Dubois, MC; Demoitié, MA; Stallaert, JF; Vansadia, P; Carter, T; Njuguna, P; Awuondo, KO; Malabeja, A; Abdul, O; Gesase, S; Mturi, N; Drakeley, CJ; Savarese, B; Villafana, T; Ballou, WR; Cohen, J; Riley, EM; Lemnge, MM; Marsh, K; von Seidlein, L; (2008) Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age. The New England journal of medicine, 359 (24). pp. 2521-32. ISSN 0028-4793 DOI: 10.1056/NEJMoa0807381

[img]
Preview
Text - Published Version
License: Copyright the publishers

Download (684kB) | Preview

Abstract

BACKGROUND: Plasmodium falciparum malaria is a pressing global health problem. A previous study of the malaria vaccine RTS,S (which targets the circumsporozoite protein), given with an adjuvant system (AS02A), showed a 30% rate of protection against clinical malaria in children 1 to 4 years of age. We evaluated the efficacy of RTS,S given with a more immunogenic adjuvant system (AS01E) in children 5 to 17 months of age, a target population for vaccine licensure. METHODS: We conducted a double-blind, randomized trial of RTS,S/AS01E vaccine as compared with rabies vaccine in children in Kilifi, Kenya, and Korogwe, Tanzania. The primary end point was fever with a falciparum parasitemia density of more than 2500 parasites per microliter, and the mean duration of follow-up was 7.9 months (range, 4.5 to 10.5). RESULTS: A total of 894 children were randomly assigned to receive the RTS,S/AS01E vaccine or the control (rabies) vaccine. Among the 809 children who completed the study procedures according to the protocol, the cumulative number in whom clinical malaria developed was 32 of 402 assigned to receive RTS,S/AS01E and 66 of 407 assigned to receive the rabies vaccine; the adjusted efficacy rate for RTS,S/AS01E was 53% (95% confidence interval [CI], 28 to 69; P<0.001) on the basis of Cox regression. Overall, there were 38 episodes of clinical malaria among recipients of RTS,S/AS01E, as compared with 86 episodes among recipients of the rabies vaccine, with an adjusted rate of efficacy against all malarial episodes of 56% (95% CI, 31 to 72; P<0.001). All 894 children were included in the intention-to-treat analysis, which showed an unadjusted efficacy rate of 49% (95% CI, 26 to 65; P<0.001). There were fewer serious adverse events among recipients of RTS,S/AS01E, and this reduction was not only due to a difference in the number of admissions directly attributable to malaria. CONCLUSIONS: RTS,S/AS01E shows promise as a candidate malaria vaccine. (ClinicalTrials.gov number, NCT00380393.)

Item Type: Article
Faculty and Department: Faculty of Infectious and Tropical Diseases > Dept of Immunology and Infection
Faculty of Infectious and Tropical Diseases > Dept of Disease Control
Research Centre: Malaria Centre
Vaccine Centre
PubMed ID: 19064627
Web of Science ID: 261534200004
URI: http://researchonline.lshtm.ac.uk/id/eprint/6543

Statistics


Download activity - last 12 months
Downloads since deposit
402Downloads
360Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item